CAS 178429-62-4
:(2R)-2-Amino-3-phenylpropylcarbamat
- Benzenepropanol, β-amino-, 1-carbamate, (βR)-
- (2R)-2-Amino-3-phenylpropyl carbamate
- Benzenepropanol, β-amino-, carbamate (ester), (R)-
- ADX-N 05
- Benzenepropanol, β-amino-, carbamate (ester), (βR)-
Solriamfetol
CAS:Kontrolliertes ProduktApplications Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor used in the treatment of sleep apnea and narcolepsy.
References Baladi, Michelle G., et al.: J. of Pharmaco. and Exper. Therap., 366(2), 367-376 (2018);Abad, Vivien C., et al.: Expert Rev. of Resp. Med., 12(12), 1007-1019 (2018);Takahashi, Tatsunori, et al.: Exp. Opin. on Orphan Drugs, 6(10), 597-610 (2018)Formel:C10H14N2O2Farbe und Form:NeatMolekulargewicht:194.23Solriamfetol-13C6
CAS:Kontrolliertes ProduktFormel:C6C4H14N2O2Farbe und Form:NeatMolekulargewicht:200.186Solriamfetol
CAS:Kontrolliertes ProduktSolriamfetol is a drug that belongs to the class of psychostimulants. It is used as an adjunct in the treatment of major depressive disorder, and has been shown to be clinically relevant in patients with major depression. Solriamfetol has been shown to have long-term efficacy and stable doses, which may be due to its chemical stability. It also has dose-dependent effects on dopamine release in the striatum, which can lead to increased symptoms of depression. The drug has also been shown to increase cardiac rate, even at stable doses and does not affect renal function. This may be because solriamfetol does not undergo oxidative injury or cause decreased glomerular filtration rate (GFR).
Formel:C10H14N2O2Reinheit:Min. 95%Farbe und Form:PowderMolekulargewicht:194.23 g/molRef: 3D-FY143183
Ausgelaufenes produkt


